Document Type : Research Paper
Authors
Abstract
111In pentetreotide (OctreoScanTM) radiopharmaceutical is used extensively for the detection of a variety of cancers in medicine. Octerotide is a pharmaceutical with a structure similar to somatostatin which is administrated via intravenous injection in an 111In labeled form. This radiopharmaceutical acts as a theranostic agent with binding to somatostatin receptors. Over the last decade, 111In pentetreotide has remained the most widely used radiopharmaceutical for the scintigraphic detection and staging of primary and metastatic neuroendocrine tumors. In this study, application of this radiopharmaceutical as well as the production and quality control strategies was investigated precisely. Briefly, the labeling yield of 111In pentetreotide was determined before the administration to the rodents. The incorporation of the radionuclide was measured by RTLC and the radiochemical purity was measured by HPLC. Due to the high thermodynamic stability constants for DTPA and In3+, the formation yield of 111In pentetreotide under the terms applied in this study was found to be high.
Keywords
[1] E.P. KrenningD, J. Kwekkeboom, W.H. Bakker, W.A.P. Breeman, P.P.M. Kooij, H.Y. Oei, M. Van Hagen, P.T.E. Postema, M. de Jong, J.C. Reubi, T.J. Visser, A.E.M. Reijs, L.J. Hofland, J.W. Koper, S.W.J. Lamberts, Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20 (1993 ) 716-731.
[2] C.M. Intenzo, S. Jabbour, H.C. Lin, J.L. Miller, S.M. Kim, D.M. Capuzzi, Scintigraphic imaging of body neuroendocrine tumors, Radiographics. 27 (2007) 1355-1369.
[3] I. Reisinger, KH. Bohuslavitzki, W. Brenner, S. Braune, I. Dittrich, A. Geide, B. Kettner, HJ. Otto, S. Schmidt, DL. Munz, Somatostatin receptor scintigraphy in small-cell lung cancer: Results of a multicenter study, J. Nucl. Med. 39 (1998) 224-227.
[4] D. Kwekkeboom, EP. Krenning, M. de Jong, Peptide receptor imaging and therapy, J. Nucl. Med. 41 (2000) 1704-1713.
[5] ET. Janson, JE. Westlin, U. Ohrvall, K. Oberg, A. Lukinius, Nuclear localization of 111In after intravenous inhection of [111In-DTPA-D-Phe1]-Octreotide in patients with neuroendocrine tumors, J. Nucl. Med. 41 (2000) 1514-1518.
[6] S. Ezziddin, T. Logvinski, C. Yong-Hing, H. Ahmadzadehfar, HP. Fischer, H. Palmedo, J. Bucerius, MJ. Reinhardt, HJ.Biersack, Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med. 47 (2006) 223-233.
[7] O. Schillaci, A. Spanu, F. Scopinaro, A. Falchi, R. Danieli, P. Marongiu, N. Pisu, G. Madeddu, G. Delle Fave, G. Madeddu, Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med. 44 (2003) 359-368.
[8] JR. Buscombe, ME. Caplin, AJ. Hilson, Long term efficacy of high-activity 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors, J. Nucl. Med. 44 (2003) 1-6.
[9] A. Capello, EP. Krenning, WA. Breeman, BF. Bernard, M. de Jong, Peptide receptor radionuclide therapy in vitro using [111In-DTPA0] octreotide, J. Nucl. Med. 44 (2003) 98-104.
[10] S. Hoegerle, C. Altehoefer, N. Ghanem, G. Koehler, CF. Waller, H. Scheruebl, E. Moser, E. Nitzsche, Whole-body 18F DOPA PET for detection of gastrointestinal carcinoid tumors, Radiology. 220 (2001) 373-380.
[11] D. Taïeb, H. Neumann, D. Rubello, A. Al-Nahhas, B. Guillet, E. Hindié, Modern nuclear imaging for paragangliomas: beyond SPECT. J. Nucl. Med. 53 (2012) 264-274.
[12] M. Duet, E. Sauvaget, B. Pételle, N. Rizzo, JP. Guichard, M. Wassef, J. Le Cloirec, P. Herman, P. Tran Ba Huy, Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck, J. Nucl. Med. 44 (2003) 1767-1774.
[13] D. Myssiorek, CJ. Palestro, 111Indium pentetreotide scan detection of familial paragangliomas. Laryngoscope. 108 (1998) 228-231.
[14] KP. Koopmans, PL. Jager, IP. Kema, MN. Kerstens, F. Albers, RP. Dullaart, 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J. Nucl. Med. 49 (2008) 1232-1237.
[15] AR. Haldemann, H. Rösler, A. Barth, B. Waser, L. Geiger, N. Godoy, RV. Markwalder, RW. Seiler, M. Sulzer, JC. Reubi, Somatostatin receptor scintigraphy in central nervous system tumors. J. Nucl. Med. 36 (1995) 403-410.
[16] JD. Lee, DI. Kim, JT. Lee, JW. Chang, CY. Park, Indium-111-Pentetreotide Imaging in Intra-axial Brain Tumors: Comparison with Thallium-201 SPECT and MRI. J. Nucl. Med. 36 (1995) 537-541.
[17] PJ. Van den Anker-Lugtenburg, EP. Krenning, HY. Oei, MP. Van Hagen, CJ. Gerrits, JC. Reubi, SW. Lamberts, B. Löwenberg, Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas, J. Nucl. Med. 42 (2001) 222-229.
[18] D. Kwekkeboom, EP. Krenning, M. de Jong, Peptide receptor imaging and therapy, J. Nucl. Med. 41 (2000) 1704-1713.
[19] WA. Breeman, M. de Jong, D.J. Kwekkeboom, R. ValkemaWillem, H. Bakker, P.P. KooijTheo, J.V. Krenning, Somatostatin receptor-mediated imaging and therapy: basic science,current knowledge, limitations and future perspectives. Eur. J. Nucl. Med. 28 (2001) 1421-1429.
[20] WA. Breeman, MT. De Jong, E. De Blois, BF. Bernard, M. De Jong, EP. Krenning, Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3] octreotide solutions containing free 90Y3+, Nucl. Med. Biol. 31 (2004) 821-824.
[21] C. Boy, TA. Heusner, TD. Poeppel, A. Redmann-Bischofs, N. Unger, W. Jentzen, W. Brandau, K. Mann, G. Antoch, A. Bockisch, S. Petersenn, 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur. J. Nucl. Med. 38 (2011) 1224-1236.
[22] TD. Poeppel, I. Binse, S. Petersenn, H. Lahner, M. Schott, G. Antoch, W. Brandau, A. Bockisch, C. Boy, Differential Uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of Gastroenteropancreatic Neuroendocrine Tumors, Recent Results Cancer Res. 194 (2013) 353-371.
[23] V. Prasad, V. Ambrosini, M. Hommann, D. Hoersch, S. Fanti, RP. Baum, Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur. J. Nucl. Med. 37 (2010) 67-77.
[24] V. Prasad, RP. Baum, Biodistribution of the Ga-68 labeled somatostatin analogue DOTANOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q. J. Nucl. Med. Mol. Imaging. 54 (2010) 61-67.
[25] A. Al-Ibraheem, RA. Bundschuh, J. Notni, A. Buck, A. Winter, HJ. Wester, M. Schwaiger, K. Scheidhauer, Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours,Eur. J. Nucl. Med. Mol. Imaging. 38 (2011) 2005-2013.
[26] WA. Breeman, M. De Jong, BF. Bernard, DJ. Kwekkeboom, A. Srinivasan, ME. Van Der Pluijm, LJ. Hofland, TJ. Visser, EP. Krenning, Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)] bombesin, a new radioligand for bombesin-receptor scintigraphy. Int. J. Cancer 83 (1999) 657-663.
[27] WA. Breeman, DJ. Kwekkeboom, PP. Kooij, WH. Bakker, LJ. Hofland, TJ. Visser, GJ. Ensing, SW. Lamberts, EP. Krenning, Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J. Nucl. Med. 36 (1995) 623-627.
[28] WA. Breeman, MP. VanHagen, HA. Visser-Wisselaar, ME. Van Der Pluijm, JW. Koper, B. Setyono-Han, WH. Bakker, DJ. Kwekkeboom, MP. Hazenberg, SW. Lamberts, TJ. Visser, EP. Krenning, In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. J. Nucl. Med. 37 (1996) 108-117.
[29] P. Jonard, J. François, Effect of peptide amount on biodistribution of Y-86-DOTA-Tyr3-octreotide (SMT487), J. Nucl. Med. 41 (2000) 260P.
[30] MC. Jebbink, JB. Jansen, FG. Van Der Kleij, DM. Mooy, LC. Rovati, CB. Lamers, Effect of duodenal juice on bombesin-stimulated cholecystokinin release during loxiglumide administration in man, Eur. J. Clin. Invest. 23 (1993) 529-533.
[31] M. Bünemann, M. Hosey, G-protein coupled receptor kinases as modulators of G-protein signalling, J. Physiol. 517 (1999) 5-23.
[32] JK. Sosabowski, SJ. Mather, Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes, Nat. Protoc. 1 (2006) 972-976.
[33] K. Chavatte, J. Mertens, D. Terriere, P. Van Den Winkel, Parameters ruling optimization of radiolabelling of polyamino polycarboxylated functionalized peptide derivatives: a case study report, Nucl. Med. Biol. 28 (2001)745-749.
[34] R. Yavari, Ar. Khanchi, H. Rafii, M.G. Maragheh, M.A. Farajzadeh, Radiochemical separation of 111In from Cd and Cu by Ion Exchange chromatography. Nucl. Sci and Tech. 34 (2005) 1-6.
[35] S.M. Moerlein, M.J. Welch, The chemistry of gallium and indium as related to radioph Optimising conditions armaceutical production. Int. J. Nucl. Med. Biol. 8 (1981) 277-287.
', './data/nct/coversheet/cover_en.jpg'))